Lyka Labs Ltd.
BSE: 500259 | Sector: Health care |
NSE: LYKALABS | ISIN Code: INE933A01014 |
BSE 00:00 | 24 Jun | 118.10 |
0.05 (0.04%) |
OPEN
117.95 |
HIGH
119.05 |
LOW
115.15 |
NSE 00:00 | 24 Jun | 118.45 |
1.15 (0.98%) |
OPEN
118.50 |
HIGH
119.50 |
LOW
116.05 |
OPEN | 117.95 |
PREVIOUS CLOSE | 118.05 |
VOLUME | 10696 |
52-Week high | 267.20 |
52-Week low | 55.75 |
P/E | 7.88 |
Mkt Cap.(Rs cr) | 339 |
Buy Price | 0.00 |
Buy Qty | 0.00 |
Sell Price | 0.00 |
Sell Qty | 0.00 |
About Lyka Labs Ltd.
Initially manufacturing formulations Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83. It also added a range of ayurvedic and animal health care products over the years. In 1990 it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson US; Airsep Corporation US; Coloplast Denmark; and Te...> More
Lyka Labs Ltd - Key Fundamentals
Parameter | Values | ||
Market Cap | (![]() |
339 | |
EPS - TTM | (![]() |
[*S] | 14.99 |
P/E Ratio | (X) | [*S] | 7.88 |
Face Value | (![]() |
10 | |
Latest Dividend | (%) | - | |
Latest Dividend Date | - | ||
Dividend Yield | (%) | 0.00 | |
Book Value / Share | (![]() |
[*S] | 15.49 |
P/B Ratio | (![]() |
[*S] | 7.62 |
Announcement
-
Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulati
-
Full And Final Payment Of Outstanding RSF 1 Facility And TL 2 Facility
-
Re-Schedulement Of 43Rd Annual General Meeting And Book Closure Period
-
Announcement under Regulation 30 (LODR)-Change in Directorate
Lyka Labs Ltd - Financial Results
Particulars (![]() |
Mar 2022 | Mar 2021 | % Chg |
Net Sales | 35.19 | 24.26 | 45.05 |
Other Income | 0.53 | 0.55 | -3.64 |
Total Income | 35.72 | 24.82 | 43.92 |
Total Expenses | 25.39 | 19.07 | 33.14 |
Operating Profit | 10.33 | 5.74 | 79.97 |
Net Profit | -15.07 | 1.14 | -1421.93 |
Equity Capital | 28.69 | 28.69 | - |
Lyka Labs Ltd - Peer Group
Company | Price(![]() |
Chg (%) | Mkt Cap (![]() |
Fredun Pharma | 847.80 | 1.69 | 377.27 |
Ind-Swift Labs. | 58.55 | 0.09 | 345.97 |
Kwality Pharma | 329.40 | -2.73 | 341.92 |
Lyka Labs | 118.10 | 0.04 | 338.83 |
Albert David | 535.65 | 6.76 | 305.86 |
Zim Laboratories | 187.25 | -2.19 | 304.09 |
Bafna Pharma. | 125.00 | 0.04 | 295.75 |
Lyka Labs Ltd - SHAREHOLDING PATTERN
|
|
Lyka Labs Ltd - RETURNS
Period | BSE | NSE | Sensex | NIFTY |
1 Week | 0.98% | 1.54% | 2.66% | 2.65% |
1 Month | -6.82% | -6.59% | -2.45% | -2.64% |
3 Month | -15.79% | -15.30% | -8.45% | -8.85% |
6 Month | -53.16% | -53.36% | -7.70% | -7.67% |
1 Year | 96.51% | 98.08% | 0.05% | -0.58% |
3 Year | 444.24% | 433.56% | 34.78% | 34.19% |
Lyka Labs Ltd - STOCK STRENGTH
Today's Low/High | 115.15 | 119.05 | |
Week Low/High | 102.50 | 123.00 | |
Month Low/High | 102.50 | 136.00 | |
YEAR Low/High | 55.75 | 267.00 | |
All TIME Low/High | 8.46 | 267.00 |
Quick Links for Lyka Labs:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices